Experimental hepatitis b drug trial halted early

NCT ID NCT02452528

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels. Only 4 people enrolled before the study was stopped, so we have very little information about how well it works or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARC-520
What this could lead to: If successful, this could point toward a more effective way to control chronic hepatitis B by reducing viral markers.
What could go wrong: This early-phase trial was terminated with only 4 participants, so results are very limited. The drug may not work or could have safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Research Site 1

San Francisco, California, 94118, United States
Research Site 2

Miami, Florida, 33136, United States
Research Site 4

New York, New York, 10029, United States
Research Site 6

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.